> Heron Therapeutics ($HRTX) announced the launch of the Phase II clinical trial of its lead candidate for the prevention of post-operative pain. It utilizes the company's proprietary drug delivery technology and is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. More
> Belgium's gene therapy biotech Celyad announced the terms of its IPO. It aims to raise $99 million through the offer of 1.4 million shares priced at $70.98 per unit. More